On Monday, Nov. 16, U.S. District Judge Mustafa Kasubhai heard arguments in a case that could broaden access to Oregon’s pioneering psilocybin therapy program. The dispute centers on whether the state‑approved therapeutic use of psilocybin – currently limited to licensed facilities – should also be available to homebound patients who cannot travel to a treatment center.
Legal challenge seeks a “reasonable modification” for disabled patients
Facilitators of psilocybin therapy filed a lawsuit in June 2024, arguing that the Oregon Psilocybin Services Act, passed by voters in 2020, should be interpreted to allow a “reasonable modification” for individuals with disabilities. Jordan Harris, an attorney representing the facilitators, told the court that many patients are confined to their homes and have no other way to receive these services.
“There’s no other way to provide services to this population other than in their homes, because they’re confined to their homes,” Harris said.
State attorneys warn of safety and statutory limits
Alexander Jones, an attorney for the Oregon Department of Justice, argued that the law expressly limits licensed facilitators to administering psilocybin at regulated facilities. He contended that the plaintiffs have not demonstrated that an in‑home model would be a “reasonable alteration” of the statute and raised concerns about safety and oversight.
Jones noted that, as of May, twenty‑two psilocybin service centers were operating in Oregon and that the Oregon Health Authority had previously denied two separate requests in 2023 to provide in‑home treatments.
Judge Kasubhai weighs federal disability law
Judge Kasubhai indicated that his decision will consider federal law prohibiting discrimination against people with disabilities. He said a ruling is expected within about 60 days.
The hearing took place at the University of Oregon School of Law, with law students in attendance, underscoring the educational importance of this emerging issue.
Why the case matters for Oregon families
If the court finds that the law can be interpreted to allow in‑home services, families caring for loved ones with serious mental‑health conditions – including end‑of‑life psychological distress – could gain a new therapeutic option without the burden of travel.
Supporters argue that the essence of Measure 109 is to provide compassionate care to all eligible adults, especially those whose disabilities make travel impossible. They see the potential expansion as a fulfillment of the voters’ intent to make psilocybin therapy widely accessible.
Potential implications
A ruling in favor of the facilitators could set a precedent for other states with regulated psychedelic programs, influencing how disability rights intersect with emerging mental‑health treatments. Conversely, a decision upholding the current facility‑only restriction would maintain the status quo, limiting access to those who can physically reach a licensed center.
The case highlights the ongoing dialogue between innovative health‑care approaches and existing regulatory frameworks, a conversation that will likely continue as more states explore psychedelic therapies.
Original reporting: Homepage – Lookout Eugene-Springfield — read the source article.